Medical & Educational Disclaimer
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Genetic data from consumer DNA tests (23andMe, AncestryDNA, MyHeritage) is not a clinical diagnostic test and does not cover every CYP2C19 variant.
CRITICAL — do not stop or change Plavix (clopidogrel) based on a DNA result. Clopidogrel is prescribed to prevent life-threatening clots after a stent, heart attack, or stroke. Stopping it without medical supervision can cause stent thrombosis, heart attack, or stroke. Only your cardiologist or prescribing physician can decide whether a medication change is appropriate — using clinical pharmacogenomic testing and your full medical history.
Short answer: your CYP2C19 gene decides whether clopidogrel (Plavix) actually works for you. Clopidogrel is a prodrug — your liver has to switch it on, and the CYP2C19 enzyme is the switch. Roughly 1 in 3 people carry a variant that blunts it: "poor" and "intermediate" metabolizers get far less clot protection on a standard prescription, while "rapid/ultrarapid" metabolizers may bleed more easily. The single most useful thing you can do today is find out which variant you carry — upload your 23andMe or AncestryDNA raw data to AskMyDNA and ask "What is my CYP2C19 metabolizer status?" Your first question is free, no credit card required. Then bring what you learn to your cardiologist.
What Is the CYP2C19 Gene and Why It Matters
CYP2C19 encodes cytochrome P450 2C19, an enzyme made mostly in your liver that breaks down — or chemically activates — a wide range of prescribed drugs. How fast your enzyme works depends on which versions of the gene you inherited from each parent.
This gene gets outsized attention in pharmacogenomics (the study of how genes affect drug response) for a practical reason: two people can take the same drug at the same dose and get very different results — not because of willpower or body size, but because their CYP2C19 enzymes run at different speeds. For most medicines that difference is manageable. For the antiplatelet drug clopidogrel (Plavix), it can have serious cardiovascular consequences.
Metabolizer Types and What They Mean
Pharmacogenomics sorts CYP2C19 function into a handful of metabolizer categories, each defined by which gene variants ("star alleles") you carry.
| Metabolizer Type | Enzyme Activity | Typical Star Alleles |
|---|---|---|
| Poor Metabolizer (PM) | None or very low | *2/*2, *2/*3, *3/*3 |
| Intermediate Metabolizer (IM) | Reduced | *1/*2, *1/*3 |
| Normal Metabolizer (NM) | Standard | *1/*1 |
| Rapid Metabolizer (RM) | Increased | *1/*17 |
| Ultrarapid Metabolizer (UM) | Highest | *17/*17 |
Because you inherit one copy from each parent, your status reflects the combination of both alleles. Someone who is *1/*2 has one working copy and one non-functional copy (intermediate); someone who is *2/*2 has no working copies (poor).
The *2 allele is common: it affects roughly 2–5% of people of European ancestry, around 15% of those of African ancestry, and up to 30% of people of East Asian ancestry. CYP2C19 poor-metabolizer status is not rare — it affects tens of millions of people. The *17 allele, which speeds the enzyme up, is most common in African and Northern European populations.
CYP2C19 and Clopidogrel (Plavix): The Key Connection
Clopidogrel is one of the most widely prescribed antiplatelet drugs in the world, given after a coronary stent, heart attack, or certain strokes to prevent dangerous clots. The critical pharmacology: clopidogrel is a prodrug. It does nothing until your liver converts it to its active form — and CYP2C19 is the primary enzyme responsible.
That creates a direct dependency:
- Poor metabolizers (PM): the liver activates very little clopidogrel, so the drug circulates largely inactive. Less antiplatelet effect — and studies show PM patients on clopidogrel after stenting have higher rates of adverse cardiovascular events, including stent thrombosis.
- Intermediate metabolizers (IM): partial activation and a reduced antiplatelet effect versus normal metabolizers.
- Normal metabolizers (NM): standard activation and the expected response.
- Rapid / ultrarapid metabolizers (RM/UM): enhanced activation; the main concern is a somewhat higher bleeding tendency.
The FDA added a boxed warning — its most serious type — to Plavix labeling, noting that poor metabolizers get reduced effectiveness and that genotype tests are available. The 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline likewise recommends CYP2C19-guided antiplatelet therapy for acute coronary syndrome and stenting.
How big is the effect? Across studies, CYP2C19 poor metabolizers treated with clopidogrel after acute coronary syndrome carry roughly 2.5–3.5× the risk of major cardiovascular events in the first year, and stent-thrombosis risk rises several-fold — most of it in the first weeks after the procedure. The risk is highest in people who also have diabetes, chronic kidney disease, or complex coronary anatomy.
To be absolutely clear: discovering you may be a poor metabolizer from a consumer DNA test is not a reason to stop Plavix. Stopping clopidogrel without medical guidance — especially soon after a stent — risks stent thrombosis, which can be fatal. Bring your result to your cardiologist or pharmacist and let them guide next steps, which may include ordering a clinical CYP2C19 test.
Why a Higher Dose Usually Isn't the Fix
A natural question is: "Can't I just take more clopidogrel?" For true poor metabolizers, generally no. The bottleneck is enzyme capacity, not dose — there simply isn't enough working CYP2C19 to activate the extra drug, so pushing the dose up tends to add side effects without restoring a normal antiplatelet effect. This is why CPIC guidance leans toward switching medication rather than escalating the dose in poor metabolizers. (Any actual dosing decision belongs to your prescriber.)
Alternative Antiplatelet Medications for CYP2C19 Variants
For people identified as poor or intermediate metabolizers, two alternatives work independently of CYP2C19, so their effect doesn't hinge on your genotype:
- Prasugrel (Effient) — a thienopyridine like clopidogrel, but activated by widespread esterase enzymes rather than CYP2C19, giving consistent, potent platelet inhibition regardless of genotype. Trade-off: a higher bleeding risk, and it's generally avoided in people with prior stroke/TIA, older age, or low body weight.
- Ticagrelor (Brilinta) — a different class that blocks the P2Y12 receptor directly, with no metabolic activation step, so it works the same across all metabolizer types. Its most common side effect is mild, usually self-limited breathlessness (dyspnea).
Both reduce cardiovascular events versus clopidogrel overall, with the largest relative benefit in poor metabolizers. Which one fits — or whether to stay on clopidogrel — is a clinical decision that weighs bleeding risk, age, kidney function, and the reason you're on antiplatelet therapy. Your genotype is one important input, not the whole answer.
CYP2C19 and PPIs: A Hidden Clopidogrel Interaction
CYP2C19 doesn't only handle clopidogrel — it also metabolizes most proton-pump inhibitors (PPIs) used for reflux and ulcers, plus some antidepressants and antifungals. That overlap matters if you take Plavix and a PPI, because certain PPIs compete for the same enzyme that activates clopidogrel:
| Drug / class | How CYP2C19 status interacts |
|---|---|
| Omeprazole, esomeprazole | Strongly CYP2C19-dependent; can further blunt clopidogrel activation. Guidelines suggest avoiding this pairing when a PPI is needed alongside Plavix. |
| Pantoprazole, rabeprazole | Much less CYP2C19-dependent; usually preferred when someone on clopidogrel also needs acid suppression. |
| Citalopram, escitalopram | Blood levels track metabolizer type; CPIC has genotype-based guidance. |
| Voriconazole (antifungal) | Poor metabolizers reach higher levels, raising side-effect risk. |
If you take clopidogrel and reach for an over-the-counter omeprazole, that's worth a quick conversation with your pharmacist — a different PPI may be the safer companion. (This is about drug choice, not adjusting anyone's dose yourself.)
Finding CYP2C19 in Your Raw Data
Consumer DNA chips (23andMe, AncestryDNA, MyHeritage) test specific single-nucleotide polymorphisms (SNPs). For CYP2C19, three show up most often and matter most:
| rsID | Star Allele | Effect | Notes |
|---|---|---|---|
| rs4244285 | *2 | Loss of function | Splicing defect; the most common loss-of-function variant globally; especially frequent in East Asian populations |
| rs4986893 | *3 | Loss of function | Premature stop codon; mainly East Asian |
| rs12248560 | *17 | Increased function | Promoter variant that raises enzyme expression (rapid/ultrarapid) |
How to read two letters. Your file shows two bases at each position (one per chromosome). At rs4244285, for example:
- A/A = two copies of *2 → likely poor metabolizer at this locus
- G/A = one *2 copy, one normal → one non-functional allele (often intermediate)
- G/G = no *2 → normal at this locus
Your full phenotype depends on rs4244285 and rs4986893 together (loss-of-function) plus rs12248560 (gain-of-function) — which is why clinical interpretation is more than reading a single SNP. Important limit: consumer chips don't sequence the whole gene, so a "normal" chip result can't rule out rarer variants. Clinical pharmacogenomic testing covers more.
How to download your raw data
- 23andMe: Settings → 23andMe Data → Download Raw Data → Request Download (confirm by email).
- AncestryDNA: DNA → Settings → Download Raw DNA Data (confirm your password; link arrives by email).
- MyHeritage: DNA → Manage DNA kits → three-dot menu → Download Raw DNA data.
For what to do with a 23andMe file given the company's turmoil, see 23andMe raw data: what to do after the bankruptcy situation.
How to find the variants in the file
Open the unzipped .txt and search (Ctrl+F / Cmd+F) for rs4244285, rs4986893, rs12248560 — each row lists the rsID, chromosome, position, and your genotype. On the command line, one search finds all three at once:
grep -E "rs4244285|rs4986893|rs12248560" your_raw_data.txt
Prefer not to hunt manually? Upload your genome to AskMyDNA and ask "Do I carry the CYP2C19 *2 allele?" — the AI reads your actual file and answers in plain language. For a broader tool comparison, see best DNA upload sites 2026, and for third-party reports, how to read a Promethease report.
How Testing Platforms Handle CYP2C19
| Platform | CYP2C19 Coverage | Notes |
|---|---|---|
| 23andMe (v5 chip) | Key SNPs (rs4244285, rs12248560); some versions include a "Clopidogrel" health report | Report availability varies by country/tier |
| AncestryDNA | SNPs present in raw data; no health interpretation | Analyze the raw file with third-party tools |
| MyHeritage | Key SNPs in raw data | Health reports via upgrade or third-party upload |
| Promethease | Annotates CYP2C19 variants via SNPedia | Paid; research context, not clinical advice |
| SelfDecode | CYP2C19 report with a personalized score | Paid; not a clinical test |
| AskMyDNA | Conversational AI that answers questions about your specific genotype | Upload your file and ask about your *2/*3/*17 status and what to discuss with your doctor |
What Your CYP2C19 Result Means (and Doesn't Mean)
What it means:
- You have real information about variants that influence CYP2C19 activity.
- If you're on clopidogrel (Plavix), it's worth discussing with your cardiologist or pharmacist.
- Your doctor may order a more comprehensive clinical pharmacogenomic test based on your consumer result.
What it doesn't mean:
- A consumer chip result is not a clinical diagnosis of your metabolizer status.
- The chip misses rarer variants; a "normal" result isn't a guarantee.
- Genotype alone doesn't fully predict drug response — dose, interactions, liver function, and clinical context all matter.
- It is never a reason to stop, reduce, or change clopidogrel on your own.
FAQ
Q: I'm a CYP2C19 poor metabolizer. Should I ask about switching from Plavix? Yes — tell your cardiologist about the finding. Whether to switch is a clinical judgment only they can make. CYP2C19-independent options (prasugrel, ticagrelor) exist but carry their own benefit–risk profiles. Do not change or stop clopidogrel on your own.
Q: My raw data shows rs4244285 as G/A — what does that mean? You carry one copy of the *2 (loss-of-function) allele and one normal *1 allele, which usually places you in the intermediate metabolizer category — reduced but not absent activity. Worth mentioning to your doctor; not the same as a poor metabolizer (*2 on both copies).
Q: Does my 23andMe report cover all CYP2C19 variants? No. Consumer chips test a selected set of SNPs (commonly *2, *3, *17). Rarer variants aren't detected, so for a medical decision a physician-ordered pharmacogenomic test is more appropriate.
Q: I take omeprazole for reflux and I'm on Plavix — is that a problem? Possibly. Omeprazole and esomeprazole lean heavily on CYP2C19 and can further reduce clopidogrel activation, so a less CYP2C19-dependent PPI (pantoprazole, rabeprazole) is often preferred. Ask your pharmacist rather than adjusting anything yourself.
Q: Are other genes involved in clopidogrel response? Several have been studied (ABCB1, CES1, PON1 and others), but CYP2C19 is the most validated and clinically significant determinant, which is why guidelines focus on it.
Q: Can AskMyDNA tell me my CYP2C19 status? Yes. Upload your raw file and ask "What is my CYP2C19 metabolizer status?" or "Do I carry the *2 allele?" It reads your actual genotype and explains what it found — and can help you prepare questions for your doctor.
Conclusion
CYP2C19 is one of the best-validated examples of pharmacogenomics in everyday medicine: a single gene whose variants can predict how well clopidogrel (Plavix) protects you. For anyone prescribed it after a stent or heart event, that's why the FDA put a boxed warning on the label — and why poor and intermediate metabolizers are often better served by CYP2C19-independent alternatives.
Your consumer DNA data gives you a window into your CYP2C19 variants. What it can't give you is a clinical interpretation of your whole medical picture — that's a conversation with your cardiologist, physician, or pharmacist. Treat your raw-data result as a starting point, not a conclusion.
If you have your raw data and want to know exactly what your CYP2C19 SNPs say, upload your genome to AskMyDNA and ask "What is my CYP2C19 metabolizer status?" — your first question is free, no credit card required. Then bring what you learn to your next appointment. You can also explore your wider pharmacogenomic profile, including CYP2D6/CYP2C19 and antidepressant response.